

Effectiveness of A Malaria Surveillance Strategy Based on Active Case Detection during High Transmission Season in the Peruvian Amazon

Diamantina Moreno-Gutierrez ^{1,2,3,*}, **Alejandro Llanos-Cuentas** ^{4,5}, **José Luis Barboza** ⁴, **Juan Contreras-Mancilla** ^{4,6}, **Dionicia Gamboa** ^{4,6,7}, **Hugo Rodriguez** ¹, **Gabriel Carrasco-Escobar** ^{6,8}, **Raphaël Boreux** ⁹, **Marie-Pierre Hayette** ⁹, **Philippe Beutels** ³, **Niko Speybroeck** ^{2,†} and **Angel Rosas-Aguirre** ^{2,4,‡}

¹ Facultad de Medicina Humana, Universidad Nacional de la Amazonía Peruana, Loreto 160, Peru; hmrodriguezf@hotmail.com (H.R.)

² Research Institute of Health and Society (IRSS), Université catholique de Louvain, 1200 Brussels, Belgium; niko.speybroeck@uclouvain.be (N.S.); angelrosasa@gmail.com (A.R.-A.)

³ Centre for Health Economics Research and Modelling Infectious Diseases, Vaccine and Infectious Disease Institute, University of Antwerp, 2000 Antwerp, Belgium; philippe.beutels@uantwerpen.be

⁴ Instituto de Medicina Tropical “Alexander von Humboldt”, Universidad Peruana Cayetano Heredia, Lima 31, Peru; alejandro.llanos.c@upch.pe (A.L.-C.); biobarbox@gmail.com (J.L.B.); juan.contreras.m@upch.pe (J.C.-M.); dionigamboa@yahoo.com (D.G.)

⁵ Facultad de Salud Pública y Administración, Universidad Peruana Cayetano Heredia, Lima 31, Peru.

⁶ Laboratorios de Investigación y Desarrollo, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima 31, Peru; gabriel.carrasco@upch.pe (G.C.-E)

⁷ Departamento de Ciencias Celulares y Moleculares, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima 31, Peru

⁸ Division of Infectious Diseases, Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA

⁹ Department of Clinical Microbiology, Center for Interdisciplinary Research on Medicines (CIRM), University Hospital of Liège, 4000 Liège, Belgium; raphael.boreux@chuliege.be (R.B.); mphayette@chuliege.be (M.-P.H.)

* Correspondence: dlmorenog@gmail.com

† These authors contributed equally to this work.

SUPPLEMENTARY MATERIAL

Table S1. Evolution of clinical status of malaria infections detected and undetected by ACD-based strategy using light microscopy (LM)

Time of detection of malaria infections by qPCR	qPCR-positive malaria infections detected by ACD-based strategy using light microscopy (LM)						qPCR-positive malaria infections undetected by ACD-based strategy using light microscopy (LM)					
	Symptomatic			Asymptomatic		Total	Symptomatic			Asymptomatic		Total
	In the same visit	In following visit (10-d later)	After 2 visits (20-d later)	After 3 visits (30-d later)	In the same visit	In following visit (10-d later)	After 2 visits (20-d later)	After 3 visits (30-d later)	In the same visit	In following visit (10-d later)	After 2 visits (20-d later)	After 3 visits (30-d later)
	n (%)	n (%)	n (%)	n (%)	n (%)	N	n (%)	n (%)	n (%)	n (%)	n (%)	N
Overall												
1st visit	20 (47.6)	5 (11.9)	2 (4.8)	0 (0)	15 (35.7)	42	56 (40.9)	13 (9.5)	8 (5.8)	2 (1.5)	58 (42.3)	137
2nd visit	5 (25.0)	4 (20.0)	2 (10.0)	ND	9 (45.0)	20	15 (18.5)	8 (9.9)	10 (12.3)	ND	48 (59.3)	81
3rd visit	14 (53.8)	3 (11.5)	ND	ND	9 (34.6)	26	8 (11.9)	8 (11.9)	ND	ND	51 (76.1)	67
4th visit	2 (15.4)	ND	ND	ND	11 (84.6)	13	8 (12.9)	ND	ND	ND	54 (87.1)	62
Total	41 (40.6)	12 (11.9)	4 (4.0)	0 (0)	44 (43.6)	101	87 (25.1)	29 (8.4)	18 (5.2)	2 (0.6)	211 (60.8)	347
<i>P. vivax</i>												
1st visit	17 (44.7)	4 (10.5)	2 (5.3)	0 (0)	15 (39.5)	38	43 (43.9)	9 (9.2)	6 (6.1)	1 (1.0)	39 (39.8)	98
2nd visit	5 (15.6)	4 (12.5)	2 (6.3)	ND	21 (65.6)	32	13 (28.3)	6 (13.0)	6 (13.0)	ND	21 (45.7)	46
3rd visit	14 (42.4)	3 (9.1)	ND	ND	16 (48.5)	33	8 (16.0)	7 (14.0)	ND	ND	35 (70.0)	50
4th visit	2 (15.4)	ND	ND	ND	11 (84.6)	13	6 (12.5)	ND	ND	ND	42 (87.5)	48
Total	38 (39.2)	11 (11.3)	4 (4.1)	0 (0)	44 (45.4)	97	70 (26.8)	22 (8.4)	12 (4.6)	1 (0.4)	156 (59.8)	261
<i>P. falciparum</i>												
1st visit	3 (100)	0 (0)	0 (0)	0 (0)	0 (0)	3	9 (34.6)	1 (3.8)	0 (0)	1 (3.8)	15 (57.7)	26
2nd visit	0 (0)	0 (0)	0 (0)	ND	0 (0)	0	2 (11.8)	0 (0)	4 (23.5)	ND	11 (64.7)	17
3rd visit	0 (0)	0 (0)	ND	ND	0 (0)	0	0 (0)	1 (12.5)	ND	ND	7 (87.5)	8
4th visit	0 (0)	ND	ND	ND	0 (0)	0	2 (14.3)	ND	ND	ND	12 (85.7)	14
Total	3 (100)	0 (0)	0 (0)	0 (0)	0 (0)	3	13 (20.0)	2 (3.1)	4 (6.2)	1 (1.5)	45 (69.2)	65
Co-infection*												
1st visit	0 (0)	1 (100)	0 (0)	0 (0)	0 (0)	1	4 (30.8)	3 (23.1)	2 (15.4)	0 (0)	4 (30.8)	13
2nd visit	0 (0)	0 (0)	0 (0)	ND	0 (0)	0	0 (0)	2 (33.3)	0 (0)	ND	4 (66.7)	6
3rd visit	0 (0)	0 (0)	ND	ND	0 (0)	0	0 (0)	0 (0)	ND	ND	2 (100)	2
4th visit	0 (0)	ND	ND	ND	0 (0)	0	0 (0)	ND	ND	ND	0 (0)	0
Total	0 (0)	1 (100)	0 (0)	0 (0)	0 (0)	1	4 (19.0)	5 (23.8)	2 (9.5)	0 (0)	10 (47.6)	21

*P. vivax-P. falciparum. ND: no data